Bcl-2 and β1-integrin predict survival in a tissue microarray of small cell lung cancer

[1]  G. Bepler,et al.  Features of Potentially Predictive Biomarkers of Chemotherapeutic Efficacy in Small Cell Lung Cancer , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  K. Kerr,et al.  Quantitative Analysis of Tumor in Bronchial Biopsy Specimens , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  G. Petrusevska,et al.  Bcl-2 as a prognostic factor for survival in small-cell lung cancer. , 2008, Prilozi.

[4]  L. El-Helw,et al.  Small-Cell Lung Cancer: 8 Years Experience of a Single Multidisciplinary Team , 2008, Journal of oncology.

[5]  C. Tse,et al.  Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models , 2008, Clinical Cancer Research.

[6]  D. L. Wilburn,et al.  Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. , 2008, Cancer research.

[7]  C. Rudin,et al.  Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Basik,et al.  Tissue microarrays: emerging standard for biomarker validation. , 2008, Current opinion in biotechnology.

[9]  C. Rudin,et al.  Fast, hungry and unstable: finding the Achilles' heel of small-cell lung cancer. , 2007, Trends in molecular medicine.

[10]  Dan H. Moore,et al.  Increased β1 Integrin Is Associated with Decreased Survival in Invasive Breast Cancer , 2007 .

[11]  H. Kato,et al.  Immunohistochemical differential diagnosis between large cell neuroendocrine carcinoma and small cell carcinoma by tissue microarray analysis with a large antibody panel. , 2006, American journal of clinical pathology.

[12]  Yeon-Hee Park,et al.  Prognostic Value of Immunohistochemical Staining of p53, bcl-2, and Ki-67 in Small Cell Lung Cancer , 2006, Journal of Korean medical science.

[13]  G. Fontanini,et al.  Applications of tissue microarray technology in immunohistochemistry: a study on c-kit expression in small cell lung cancer. , 2004, Human pathology.

[14]  J. Verdebout,et al.  Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis , 2003, British Journal of Cancer.

[15]  C. Zettler,et al.  p53 and Bcl-2 protein expression and its relationship with prognosis in small-cell lung cancer. , 2003, Clinical lung cancer.

[16]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[17]  Y. Kameda,et al.  Increased expression of integrin beta1 is a poor prognostic factor in small-cell lung cancer. , 2002, Anticancer research.

[18]  P. Krammer,et al.  Upregulation of bcl‐2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines , 2002, International journal of cancer.

[19]  G. Giaccone,et al.  Expression of DNA topoisomerase IIalpha and topoisomerase IIbeta genes predicts survival and response to chemotherapy in patients with small cell lung cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  G. Giaccone,et al.  Second-line chemotherapy and its evaluation in small cell lung cancer. , 1999, Cancer treatment reviews.

[21]  R. Ashfaq,et al.  Survival in small cell lung carcinoma is independent of Bcl-2 expression. , 1999, Human pathology.

[22]  Christopher Haslett,et al.  Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: A mechanism for small cell lung cancer growth and drug resistance in vivo , 1999, Nature Medicine.

[23]  M. Parmar,et al.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. , 1998, Statistics in medicine.

[24]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[25]  D. Allred,et al.  Prognostic and predictive factors in breast cancer by immunohistochemical analysis. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[26]  H. Kreipe,et al.  Expression of bcl-2--protein in small cell lung cancer. , 1996, Lung cancer.

[27]  Y. Nakanishi,et al.  Bcl-2 expression as a predictor of chemosensitivities and survival in small cell lung cancer. , 1996, The cancer journal from Scientific American.

[28]  John Calvin Reed,et al.  The alpha 5 beta 1 integrin supports survival of cells on fibronectin and up-regulates Bcl-2 expression. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[29]  G. Bepler,et al.  Establishment and identification of small cell lung cancer cell lines having classic and variant features. , 1985, Cancer research.

[30]  S. Kang,et al.  Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with small cell lung cancer. , 2008, Lung cancer.

[31]  Hui Zhang,et al.  Increased beta1 integrin is associated with decreased survival in invasive breast cancer. , 2007, Cancer research.